AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Core Points - AIM ImmunoTech Inc. is participating in the Virtual Investor "Top 5 for '25" On-Demand Conference, where the CEO presented five key reasons for investment interest in the company in 2025 [1][2] Group 1: Company Developments - Progress in late-stage pancreatic cancer treatment with significant advancements in the Phase 1b/2 DURIPANC trial at Erasmus Medical Center in the Netherlands [6] - Expanding research in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and post-COVID conditions, highlighting the early recognition of the link between COVID-19 and ME/CFS-like conditions [6] - Rapid advancement across the oncology pipeline with multiple key trials reaching or approaching major milestones [6] Group 2: Product Focus - Plans to advance Ampligen as a vaccine adjuvant for the growing threat of bird flu, as part of the company's antiviral priority development pipeline [6] - Ampligen's overall potential as a broad-spectrum immunotherapy [6] Group 3: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod) [3]